Affinity Asset Advisors, LLC Cytokinetics Inc Transaction History

Affinity Asset Advisors, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$63.75 - $108.06 $5.1 Million - $8.64 Million	-80,000 Reduced 50.0%	80,000 $5.61 Million
Q4 2023 Feb 13, 2024	SELL	$26.88 - $83.49 $1.89 Million - $5.87 Million	-70,366 Reduced 30.55%	160,000 $13.4 Million
Q3 2023 Nov 14, 2023	BUY	$29.46 - $36.61 $3.1 Million - $3.85 Million	105,218 Added 84.07%	230,366 $6.79 Million
Q2 2023 Aug 14, 2023	SELL	$32.62 - $40.75 $3.14 Million - $3.92 Million	-96,315 Reduced 43.49%	125,148 $4.08 Million
Q1 2023 May 15, 2023	BUY	$33.36 - $45.71 $4.47 Million - $6.12 Million	133,862 Added 152.81%	221,463 $7.79 Million
Q4 2022 Feb 13, 2023	BUY	$35.77 - $51.11 $808,437 - $1.16 Million	22,601 Added 34.77%	87,601 $4.01 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $1.93 Million - $2.73 Million	50,000 Added 333.33%	65,000 $3.15 Million
Q2 2022 Aug 12, 2022	BUY	$33.93 - $48.92 $508,950 - $733,800	15,000 New	15,000 $589,000
Q1 2022 May 13, 2022	SELL	$29.74 - $46.0 $4.33 Million - $6.7 Million	-145,552 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$34.35 - $46.38 $705,961 - $953,201	20,552 Added 16.44%	145,552 $6.63 Million
Q3 2021 Nov 12, 2021	BUY	$18.54 - $35.74 $1.02 Million - $1.97 Million	55,000 Added 78.57%	125,000 $4.47 Million
Q2 2021 Aug 13, 2021	BUY	$19.79 - $26.99 $593,700 - $809,700	30,000 Added 75.0%	70,000 $1.39 Million
Q1 2021 May 14, 2021	SELL	$18.57 - $25.68 $557,100 - $770,400	-30,000 Reduced 42.86%	40,000 $930,000
Q4 2020 Feb 12, 2021	BUY	$15.26 - $28.61 $1.07 Million - $2 Million	70,000 New	70,000 $1.46 Million

407

125M

4.6M

2.42M

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.03B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.